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Quality assuranceAbstract Proposals to improve implementation, monitoring and evaluation of breast, cervi-
cal and colorectal cancer screening programmes have been developed in a European project
involving scientists and professionals experienced in cancer registration (EUROCOURSE).
They call for a clear and more active role for cancer registries through better interfaces with
cancer screening programmes and adapting data contents of cancer registries for evaluation
purposes. Cancer registries are recognised as essential for adequate evaluation of cancer
screening programmes, but they are not involved in screening evaluation in several European
countries. This is a key barrier to improving the effectiveness of programmes across Europe.
The variation in Europe in the implementation of cancer screening offers a unique opportu-
nity to learn from best practices in collaboration between cancer registries and screening pro-
grammes. Population-based cancer registries have experience and tools in collecting and
analysing relevant data, e.g. for diagnostic and therapeutic determinants of mortality. In order
to accelerate improvements in cancer control we argue that cancer registries should take
co-responsibility in promoting effective screening evaluation in Europe. Additional investments
are vital to further development of infrastructures and activities for screening evaluation and
monitoring in the national settings and also at the pan-European level. The EUROCOURSE
project also aimed to harmonise implementation of the European quality assurance guidelines
for cancer screening programmes across Europe through standardising routine data collection
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242 A. Anttila et al. / European Journal of Cancer 51 (2015) 241–251and analysis, and deﬁnitions for key performance indicators for screening registers. Data link-
age between cancer and screening registers and other repositories of demographic data and
cause of death and where available clinical registers is key to implementing the European
screening standards and thereby reducing the burden of disease through early detection.
Greater engagement of cancer registries in this collaborative effort is also essential to develop
adequate evaluation of innovations in cancer prevention and care.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction: the challenge
Detection of cancer in its early stages in combination
with prompt, appropriate treatment has become an
important element in cancer control in recent decades.
The aim of early detection is to reduce mortality and
other serious consequences of advanced disease. In the
case of cervical or colorectal cancer screening, incidence
can also be reduced. Reduction of mortality may be
accomplished if earlier treatment improves life expec-
tancy, loco-regional control of disease and quality of life
and/or permits equally eﬀective therapy with fewer side-
eﬀects (Fig. 1). Universal access to prompt and eﬀective
diagnosis and treatment is a key to achieve the potential
impact of early detection of cancer [1]. The concept of
early detection of cancer has evolved since the 1968
report of the World Health Organisation (WHO) [2].rlier detection of selected
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complex than the steps outlined above. Throughout
the process, balanced information must be provided to
participants and programme owners on the beneﬁts
and harms of the services provided. This information
must be based on systematic monitoring and evaluation
that takes into account the complexity of the screening
process.
In the following, the term ‘cancer registry’ is used to
refer to the institution managing the databases (‘cancer
register’) on the occurrence of cancer in the region
served by the registry. The term ‘screening registry’ is
used to refer to the institution managing the databases
(‘screening register’) required for the documentation of
the screening programmes and services. In practice, the
same institution may manage both registers, or more
than one institution may be responsible for the collec-
tion, checking and storage of some or all of the data
in these registers. It is essential that these registries are
not only responsible for managing the databases, but
also for the interpretation and reporting of results and
are engaged in the design of studies, in evaluation of
screening, use of data for scientiﬁc purposes and in
assuring that high quality data is available to other
researchers for further investigation.
To achieve an appropriate balance between harm and
beneﬁt, comprehensive multidisciplinary guidelines for
quality assurance in cancer screening have been devel-
oped [6–9]. They include monitoring of organisational,
technical and professional performance and evaluation
of impact as integrated parts of cancer screening pro-
grammes. Application of these key components across
Europe has been limited to date, however [10,11], prevent-
ing opportunities to exchange experience between pro-
grammes. The main barriers to this progress have been:
– underdeveloped standards for documentation and
reporting of cancer screening programmes;
– lack of an appropriate mandate, sustainable institu-
tional infrastructure and adequate resources for sys-
tematic collection, analysis and reporting of the
monitoring and evaluation data and results;
– wide variation in application of standards at national
and/or regional level.
Therefore, scientists and professionals experienced in
monitoring and evaluation of cancer screening collabo-
rated in a European project (EUROCOURSE) [12]
and designed a series of recommendations for data inter-
faces between cancer registries, screening programmes
and other information sources. The present paper pro-
vides an overview of the data items and key performance
indicators that cancer screening registries should collect,
or have access to for standardised, regular monitoring at
the regional, national and European level. It also reports
the additional information to be acquired by and frompopulation-based cancer registries that is essential in
improving the quality and eﬀectiveness of cancer screen-
ing. Cancer registries are increasingly involved in assess-
ing progress against cancer [13] and need to improve
their capacity to assess the impact of cancer screening
on the overall burden of cancer. Endorsement and
implementation of the present suggestions to improve
registration practices will be crucial to the success of
these eﬀorts in Europe and other continents.
2. Approach followed
Systematic review of the relevant standards, protocols
and other recommendations in the European guidelines
for quality assurance in breast, cervical and colorectal
cancer screening was performed by an expert working
group (see Acknowledgement) [6–9]. Additional relevant
information was derived from the results of the activities
of the work groups on registration of cancer screening in
the former EU-funded project “European Network for
Information on Cancer” (EUNICE) [14,15], and relevant
recommendations of the European Network of Cancer
Registries (ENCR) [16]. Based on these reviews, joint
recommendations to improve the capability of cancer
registries were developed. The potential of registries to
improve the balance between beneﬁt and harm of screen-
ing was also examined by reviewing the current knowl-
edge from trials on lung and prostate cancer screening.
Key results and conclusions for future improvement
are publicly available [17] and have been recently used
to update the European guidelines for quality assurance
in cancer screening and diagnosis [8].
3. Considerations and recommendations
3.1. European data set for monitoring cancer screening
One of the key objectives of cancer screening regis-
tries is to monitor performance of cancer screening pro-
grammes and services by collecting, storing and
reporting the information needed to support eﬀective
management and to assess services. These activities
require a comprehensive data matrix that includes:
– description of the organisational settings delivering
the screening services,
– characteristics or events that each variable describes,
– relevant coding standards for the data items underly-
ing each variable.
The matrix should be used to continuously generate
reports using standard sets of indicators for monitoring
performance of screening programmes. The recom-
mended short and long-term indicators for each target
cancer (Tables 1–3) refer to screening protocols com-
monly used in Europe in 2010–2012 and also later years:
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– cytology (pap) testing for cervical cancer,
– guaiac-based (gFOBT) or immunochemical (FIT)
faecal occult blood test for colorectal cancer.
Indicators speciﬁc to other validated screening proto-
cols are available for sigmoidoscopy for colorectal can-
cer [9] or are being developed, such as for primary
Human Papillomavirus (HPV) testing in a cervical can-
cer screening programme.
Screening registries should also have access to infor-
mation on any relevant diagnostic tests and treatments,
i.e. also if they are performed outside of the programme
[6]. Otherwise it is not possible to eﬀectively manage the
factors impacting on the outcome and cost-eﬀectiveness
of the screening programme. In addition the opportunity
to avoid unnecessary testing outside the screening
programme and thereby strengthen societal and health-
economic beneﬁts of quality assured screening pro-
grammes cannot be fully exploited without full informa-
tion about relevant diagnostic tests and treatments
outside the programme. Use of screening services outsideTable 1
Description of performance indicators to be generated for European moni
Indicator Numerator
Extension by screening programme N target population within the ar
organised screening programme
Coverage by invitation N women invited during time fram
Coverage by examination N women screened during time fr
Participation rate N women invited and screened in
Further assessment rate N screened and referred to furthe
Compliance with further assessment N participated in further assessme
Technical repeat rate N with a recall for technical reaso
Intermediate mammography rate N screened out of sequence with t
interval
Referral to treatment rate N referred to surgery or to neo ad
or inoperable cancer
B/M ratio N with benign histological diagno
Cancer detection rate (in situ
included)
N with histologically conﬁrmed in
cancer
Ductal carcinoma in-situ (DCIS)
detection rate
N with DCIS
Invasive cancer detection rate
(invasive)
N with invasive breast cancer
Benign biopsy rate N with benign histology
Small invasive cancers as proportion
of invasive cancers
N with invasive cancer with pT 1A
Node negative cancers/total cancers
screen-detected
N with lymph nodal status negati
Stage II + breast cancers/total
cancers screen-detected
N with pTNM stage IIA to IV
Stage II + breast cancers/total
screened women
N with pTNM stage IIA to IV
Interval cancer Cancer in screen negatives or epis
during the interval
Conservative therapy (DCIS) N with DCIS with breast conserv
Conservative therapy (invasive) N with invasive cancer with breas
surgery
Conservative therapy (pT1) N with pT1 invasive cancer with b
surgerythe population-based programme and policies permitting
such use, still constitute a major barrier to achieving
appropriate and cost-eﬀective services in several coun-
tries. Tables 1–3 provide only a few examples of treatment
indicators, as screening programmes should liaise with
specialist clinical units for appropriate quality assurance
of screen-detected as well as of clinical cases [18].
The screening registers should also record whether
the test was performed in opportunistic screening, or
due to clinical indication or management. They should
also maintain accessible, complete records giving basic
descriptions of the various data sources, coding struc-
tures and programme policies, and any other relevant
data structures; including data generated by linkages.
Detailed examples of individual-level coding struc-
tures in use with screening registries to record the data
needed to generate the variables and produce the
indicators for each target cancer are publically available
as one of the ﬁnal products of the EUROCOURSE
project (see annexes 1–3 at [17]). For completeness and
accuracy, the screening database must include indexing
throughout all episodes (i.e. from test to recommenda-toring data on breast cancer screening.
Denominator
ea with the N of population with corresponding age and gender
within the whole country
e N women in target population
ame N women in target population
episode N women invited in episode
r assessment N screened
nt N referred to further assessment
ns N screened
he screening N screened
juvant therapy N screened
sis (ratio) N with histologically conﬁrmed in situ or
invasive cancer
situ or invasive N screened
N screened
N screened
N screened
or 1B N with invasive cancer
ve N with invasive cancer
N with invasive cancer
N screened
ode negatives
ing Surgery N with DCIS operated
t conserving N with invasive cancer
reast conserving N with pT1 invasive cancer
Table 2
Description of performance indicators to be generated for European monitoring data on cervical cancer screening.
Indicator Numerator Denominator
Extension by screening programme N target population within the area with the
organised screening programme
N of population with corresponding age and
gender within the whole country
Coverage by invitation N women invited during time frame N women in target population
Coverage by examination N women screened during time frame N women in target population
Compliance to invitation N invited and screened women in episode N invited women in episode
Incidence of fully invasive cancer in
unscreened and underscreened women
N fully invasive cancers detected in women
not screened within interval
N person-years of women not screened for
interval
Distribution of screened women by the results
of cytology
N of women with each cytological diagnosis N women screened in programme
Referral rate for repeat cytology N screened women recommended for repeat
screening after shorter interval
N women screened in programme
Compliance with referral for repeat cytology N women screened after shorter interval N women recommended for shorter interval
Referral rate for colposcopy N women referred for colposcopy N women screened in programme
Positive predictive value (PPV) of referral for
colposcopy
N women with histologically conﬁrmed
CIN1+/CIN2+/CIN3+
N women with colposcopy
Test speciﬁcity N screened women not referred for
colposcopy
N screened women with no CIN1+/CIN2+/
CIN3+
Detection rate by histological diagnosis N screened women with each histological
diagnosis
N women screened in programme
Cancer incidence after normal cytology N screened women with fully invasive cancer
within interval after normal test
N person-years of women with normal test for
interval
Compliance to referral for colposcopy N screened women who attended colposcopy N women referred for colposcopy
Treatment of intraepithelial lesions N women with treated screen-detected lesions
CIN1/CIN2/CIN3
N women with screen-detected lesions CIN1/
CIN2/CIN3
Proportion of women hysterectomised on
screen-detected intraepithelial lesions
N women hysterectomised on histological
CIN1/CIN2/CIN3
N women with histological CIN1/CIN2/CIN3
Incidence of non-screen-detected fully invasive
cancer after abnormal cytology
N cases of invasive cancer after abnormal
cytology
N person-years of screened women after
abnormal cytology
Table 3
Description of performance indicators to be generated for European monitoring data on colorectal cancer screening.
Indicator Numerator Denominator
Extension by screening
programme
N target population within the area with the organised
screening programme
N of population in corresponding age groups
within the whole country
Invitational coverage N invited during time frame N eligible in target population
Coverage by examination N screened or tested during time frame N eligible in target population
Compliance to invitation (uptake
rate)
Screened Invited
Rate of inadequate tests Inadequate Screened
Rate of test positives Positive test result Screened
Referral rate to colonoscopy after
positive test
Referred N with a positive test result
Compliance to colonoscopy Colonoscopied Referred
Rate of complete colonoscopies Complete colonoscopies Total colonoscopied
Biopsy rate Biopsy taken Colonoscopied
Lesion detection rate N with at least one lesion Screened
Adenoma detection rate N with at least one adenoma Screened
Advanced adenoma detection rate N with at least one advanced adenoma Screened
Cancer detection rate N with at least one cancer Screened
PPV for detection of lesions N with at least one lesion N with colonoscopy
PPV for detection of adenoma N with at least one adenoma N with colonoscopy
PPV for detection of advanced N with at least one advanced adenoma N with colonoscopy
PPV for detection of cancer N with at least one cancer N with colonoscopy
Endoscopic complications N with complication N with colonoscopy
Interval cancer Cancer in screen negatives or episode negatives during
the interval
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use of unique personal identiﬁers to compile the full
information of an individual over multistep screening
episodes, and to link this information to other datasources in health-care. The internal and external quality
of the screening registers needs to be regularly checked
by the responsible staﬀ and errors continuously
corrected. Final, comprehensive quality control of
246 A. Anttila et al. / European Journal of Cancer 51 (2015) 241–251information about cancer cases and other data items
included in the cancer register should be conducted rou-
tinely by the cancer registry. Screening registries need to
pass their information to cancer registries to enable this
quality control, and in return will be able to utilize reli-
able data on cancers. The multiple data sources may
also permit more accurate diﬀerentiation between inva-
sive and precancerous lesions throughout the diagnostic
process. The following data items in screening registers
are generally not included in the cancer registry domain:
results of the screening test and related assessment of
abnormalities detected, and treatment, and thus system-
atic data quality control procedures are needed also in
the screening registers for these items.3.2. Collection and linkage of screening registry data
The data collected by screening registries should per-
mit generation of aggregated performance indicators for
comparative monitoring at the European level (Tables
1–3). Every cancer screening registry should adopt stan-
dard collection procedures that utilise electronic data,
coded according to standard practice within the respec-
tive health-care system. The data input can be con-
densed and processed further by the screening registry
in order to generate the variables needed to produce
the standard performance indicators.
Data essential to monitoring and evaluation of cancer
screening programmes are not only stored in cancer reg-
istries and screening registries. It must also be obtained
by linkage of these with population registers, cause of
death registers, and – where available – clinical registers
of diagnostic and treatment services such as hospital and
outpatient registers. Relevant information must also be
obtained from vaccination registers (human papilloma
virus, HPV) and biomaterial archives. Unique personal
identiﬁers should be used in all of the registers to permit
eﬀective linkage for data access and to control data
quality. For example, cause of death statistics may be
less accurate for a given cancer site than cancer registry
data because the latter utilise multiple data sources.3.3. Innovations in cancer registration to improve
evaluation of screening
In the context of cancer screening, the role of the can-
cer registry is to collect, analyse and report information
needed to reliably assess the impact of the programme
on the burden of disease in the population. Ultimately
disease-speciﬁc mortality, but, especially for cervical or
colorectal cancer screening, disease- and age-speciﬁc
incidence must also be evaluated. The evaluation organi-
sation also needs information on those adjuvant and
palliative treatments that lower cancer mortality or
improve quality of life of cancer patients. The additional
data and legal framework that are needed are outlinedbelow. The suggestions reported here should be incorpo-
rated into the standards and procedures adopted by the
cancer registration community.
3.3.1. Reporting pre-cancerous lesions
Data on pre-cancerous lesions are needed to weigh
the achieved beneﬁt of screening in the light of potential
harm by detecting and treating pre-cancerous lesions,
many of which would not progress to cancer for a long
time if left untreated. Comprehensive screening registers
are the primary source for these data in combination
with the cancer registry.
Cancer registries should record cases of high-grade
intraepithelial cervical dysplasia and in situ cancers
(CIN3/AIS). Micro-invasive cervical carcinoma and
CIN3/AIS with separate codes in ICD-O-3 classiﬁcation
of morphology should therefore be recorded separately
(from each other or from fully invasive cancer). Screen-
detected cancers in the micro-invasive phase appear to
be better treatable and result in lower mortality than fully
invasive cancers. In addition, anal, vaginal, and vulvar
intraepithelial dysplasia (AIN3, VAIN3, VIN3) are pre-
invasive lesions that may be aﬀected by screening activi-
ties, and are now reported only to some cancer registries.
In situ carcinoma of the breast should also be
recorded in the cancer registry. Ductal carcinoma in-situ
(DCIS) of the breast is included in ICD-O-3 and should
be separately tabulated from invasive cancer (see recom-
mendation below on multiple primaries). Current cancer
registry practices vary with regard to the choice of the
date of DCIS or of the invasive cancer when diagnosed
within a short period of time.
For colorectal cancer, recording of advanced adeno-
mas is essential for the evaluation of cancer screening
programmes because such data of non-attenders are
not available in screening registries. There is also a need
to standardise the deﬁnition of an advanced adenoma
for registration purposes as the existing Systematized
Nomenclature of Medicine (SNOMED) or WHO classi-
ﬁcations do not deﬁne these lesions adequately. We sug-
gest to adopt the criteria used in the European quality
assurance guidelines for colorectal cancer screening that
deﬁne an advanced colorectal adenoma as one that is
either P10 mm or contains high-grade mucosal neopla-
sia or a villous component [19]. As for other pathologic
criteria such as villous morphology, there is no universal
agreement to include them in the registration.
3.3.2. Validation of the mode of detection
Reporting the mode of detection, i.e. the screening
status at the time of detection:
– before ﬁrst or after last invitation,
– invited, but not attended,
– screen-detected,
– interval cancer, and
– not invited
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provides information that helps to explain the extent
to which a screening programme impacts on the burden
of disease in the target population and the population as
a whole. Mode of detection is a reliable variable only if
produced through systematic linkage of screening and
cancer registers.
At the time of reporting the tumour to the cancer reg-
istry, the screening status of the cancer case may not be
known. Linkage with the screening registry may there-
fore need to be performed over one or more full screen-
ing rounds. For practical reasons, linkages for assessing
the mode of detection should be carried out by the
screening programme monitoring system and the results
should be made available for all cancer cases of the pri-
mary sites targeted by screening programmes also in the
regular cancer registry statistics.3.3.3. Consistent registration of incidence date
To assign an incidence date, consistent rules should
be applied from the ENCR priority list [15]. Further-
more, the availability of subsequent dates in the assess-
ment pathway is useful for quality assurance and related
studies of cancer screening. Recording a minimum set of
dates, e.g. ﬁrst diagnostic visit, ﬁrst diagnostic specimen,
pathology report, and sources of such information will
promote comparability of data between registries.3.3.4. Multiple primaries
To permit eﬀective screening evaluation, all primaries
should be collected and coded as separate cancers. Only
one of these primaries would be the “incident” case. In
principle, this approach is consistent with the current
ENCR recommendation, but some adjustment in detail
is needed. For example, lobular and ductal breast carci-
nomas should be considered as diﬀerent morphology, i.e.
as separate cancer cases, in departure from the ENCR
coding rule 3 of the A1.2 recommendations for coding
multiple primaries. Synchronous or metachronous
breast cancer in diﬀerent breasts, even if of the same mor-
phology, should also be recorded as multiple primaries.
DCIS may not only pose a problem due to the poten-
tial for multiple primaries. If DCIS is followed by inva-
sive recurrence, the latter tumour becomes the incident
cancer according to current coding rules. However,
detection of DCIS is important information in the man-
agement of breast cancer, even if it is the ﬁrst diagnosis.
All DCIS should be recorded so that all cases can be
included in further quality assurance databases for can-
cer screening programmes.
Concerning CIN/AIS and cervical cancer, in non-
advanced cancers, areas of intraepithelial neoplasia
usually coexist with areas of invasion. Not infrequently,
a high-grade CIN is diagnosed on a punch biopsy and
invasion is observed shortly thereafter on the Loop
Electrosurgical Excision Procedure (LEEP)/conisationspecimen, suggesting that the cancer already existed
when the biopsy was taken. However, CIN3 can of
course progress to invasion if untreated, or even despite
treatment. Plausibly, CIN3 should be registered sepa-
rately if diagnosed over a certain time interval before
cancer is detected and not if diagnosed afterwards.3.3.5. TNM for coding the extent of disease
The ENCR recommends full TNM Classiﬁcation of
Malignant Tumours (TNM) and, if not available, a con-
densed TNM (coding the extent of disease). Full TNM
Classiﬁcation of Malignant Tumours, stage given by
pathologic examination of a surgical specimen (pTNM)
based on pathology reports on screen-detected cases
should be the recording standard. Speciﬁcally for colo-
rectal cancer, information on the depth of cancer inva-
sion is more important than the size of the tumour.
The former cannot be derived from the condensed
TNM. In addition, the location of the tumour should
be recorded according to ICD-0-3 topography. The full
clinical TNM (cTNM) should be included in the cancer
registry information as a separate code. Cancer registries
should aim to record the exact size of screen-detected
tumours in millimetres.3.3.6. Ethical and legal framework for quality assurance
Availability of individual data in the cancer registry
for linkage to data in the screening registry is crucial
to quality assurance of the screening programme and
other oncologic services. Developing the appropriate
legal and technical framework for data collection and
linkages is an important responsibility of any authorities
responsible for screening programmes [20]. The legal
frameworks for the diﬀerent systematic registries in a
given health care system are quite similar. If cancer reg-
istries have a comprehensive, oﬃcial responsibility in the
assessment of the quality of screening and clinical care,
the legal and technical aspects should become less com-
plicated than with separate evaluation systems.4. Discussion
Considerable experience has gradually developed in
Europe in successful implementation of population-
based cancer screening programmes [6–9,14,21–23]. All
of the EU countries have piloted or implemented or
are currently in the process of planning implementation
of at least one of the three recommended cancer
screening programmes (breast, cervix or colorectal).
Population-based organisation and implementation
with quality assurance of every step in the screening pro-
cess from invitation to testing, diagnosis, treatment and
surveillance is the cornerstone of the recommended
European approach [5,21,23]. Eﬀective implementation
begins with asking the right questions about the pro-
gramme design, and includes development and testing
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system. This requires development of capacity to eﬀec-
tively monitor short- and medium-term professional
and technical performance and to recognise changes in
performance over time in order to continuously improve
the screening service and to take corrective action, if
necessary.
The expert working group that developed the present
recommendations also pointed out the need for closer
collaboration between screening programmes and popu-
lation-based cancer registries, not only to eﬀectively gen-
erate the requisite performance indicators, but also to
interpret the data correctly. The direct exchange of
information between the cancer registry and clinical spe-
cialists contacted to verify data can result in a better
interpretation of data and improvements in clinical per-
formance. Given the many years required to assess the
impact of a screening programme on the population
burden of cancer, current results of performance moni-
toring must be correlated with the future estimated
results of evaluation studies. By the same token, assess-
ment of the harms of screening, such as overdiagnosis
and overtreatment – especially a problem when detec-
tion techniques become more sensitive – requires a sim-
ilar approach, collaboration and data linkage.
Continuous, eﬀective monitoring of screening perfor-
mance is therefore necessary for timely interpretation
of the emerging results even when the long-term evalua-
tion studies of cancer screening are not yet available for
the particular programmes.
Whereas the health authorities in the EU member
states have increasingly embraced the European policy
of recommending population-based programmes for
breast, cervical or colorectal cancer screening using evi-
dence-based methods and following the European qual-
ity assurance guidelines [23], awareness has only recently
been raised for the importance of investment in infra-
structure for comprehensive performance monitoring
and long-term impact evaluation of screening pro-
grammes. The supplement to the 4th edition of the
European guidelines for quality assurance in breast can-
cer screening and diagnosis points out that successful
implementation of eﬀective cancer screening pro-
grammes requires signiﬁcant resources for quality assur-
ance i.e. 10–20% of total expenditure (see Box 1) [24,25].
This proportion is based on experience in implementing
population-based cancer screening programmes in
Europe. The lower end of the range is more applicable
to very large, less complex programmes with substantial
economies of scale. In the initial years, this proportion
may be substantially higher due to the low volume of
screening examinations compared with the situation
after complete rollout of a nationwide programme. A
substantial proportion of these resources is required
for well-organised information systems, such as thosein use by screening registries and population-based
cancer registries, to assure the quality of the screening
service and appropriate action following a positive
screening test; and to monitor performance and evaluate
the impact of any screening programme [1,24]. Quality
assurance also includes timely, prospective evaluations
of modiﬁcations of existing programmes and piloting
of new programmes. Adherence to these principles and
recommendations is an ethical imperative to assure that
the screening services delivered to the population are
appropriate.
Nationwide, population-based registration of breast,
cervical and colorectal cancer is not yet feasible in all of
the EU member states. In 2012 cancer registry coverage
of the combined European populations was somewhat
more than 60%. Systematic evaluation of cancer control
and quality of care remained modest, except in a few ded-
icated CRs. Respectively, evaluation of mass screening
programmes was supported more or less routinely by
only 44% of CRs. [26]. Comprehensive cancer screening
registries with the capacity to regularly link and closely
collaborate with the cancer registry are unfortunately
an exception [27,28]. In a recent review of longitudinal
cohort follow-up studies that linked a woman’s screening
history to cause of death, the authors estimated a reduc-
tion in breast cancer mortality by 25–31% for women
invited for screening [29]. This study design was possible
only using regional data from Denmark, Finland, Italy,
Norway and Sweden [29,30]. Developing availability of
data details and particularly also appropriate legal
frameworks enabling screening-related public-health
research activities utilising the register-based infrastruc-
tures [31,32] are crucial to the future development of
European cancer registries. Evaluation of clinical and
diagnostic quality irrespective of cancer screening is also
very important, there are synergies with this area of
research and evaluation of cancer screening programmes
(see Box 2). Cancer registries are increasingly engaged in
the assessment of the quality of care of those oncological
services that are not involved in cancer screening. For the
cancer sites targeted by cancer screening programmes,
screening registries can provide a basis for developing
the systematic population-based quality care registers.
Evidence-based and quality-assured cancer screening
can stimulate health systems to raise standards of care
within and outside the programme; population-based
screening also raises awareness of cancer symptoms
among healthcare professionals and the general public.
Training of professionals and quality assurance in diag-
nosis, staging and treatment in the screening programme
have the potential to improve cancer prevention and care
across the board. These factors, in combination are likely
to have contributed to declines in mortality from cervical
and breast cancers in countries or regions with ongoing
population-based screening programmes.
Box 2 Innovations in population-based cancer regis-
tries to ensure the quality of cancer screening pro-
grammes through monitoring and evaluation.
!Mandating and adequately resourcing cancer regis-
tries to accept co-responsibility for the quality and
impact assessment of screening programmes.
!High quality recording of precancerous lesions:
– high-grade cervical intraepithelial neoplasia, and in
situ carcinoma of the cervix.
– in situ carcinoma of the breast.
– advanced colorectal adenomas, and colorectal
polyps with high-grade dysplasia.
– high-grade vaginal, vulvar and anal dysplasia.
!Recording mode of detection of cancer or
precancer.
!Applying consistent rules to deﬁnition of incidence
date and separate recording of multiple primaries
(synchronous and metachronous), micro-invasive-
ness, TNM (pathological and clinical) and location.
!Using the whole information chain to evaluate the
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Monitoring and evaluation are essential to quality
assurance of population-based cancer screening pro-
grammes. Concerted investments are needed to develop
data collection systems and to enable competent centres
such as screening and cancer registries to collaborate in
linking and analysing the requisite data.
Harmonised data collection and analysis, and regular
exchanges of experience and results between pro-
grammes and competent evaluation centres at the regio-
nal, national and European level will accelerate
improvement in cancer screening and thereby reduce
the burden of breast, cervical and colorectal cancer in
Europe. This support will also lay the foundation for
future eﬀorts e.g. if prostate or lung cancer screening
become an option across Europe.
Population-based cancer registries have experience
and tools in collecting and analysing relevant data for
cancer prevention and diagnostic and therapeutic deter-
minants of mortality. Greater engagement of cancer reg-
istries in monitoring and evaluation of cancer screening
programmes is essential to improve the programmes and
to permit better overall assessment of progress against
cancer, taking into account changes in prevention and
quality of treatment.Box 1 Requirements for eﬀective implementation of
cancer screening programmes.
!Engagement of population-based registries for can-
cer, population, patient-clinical data and screening,
all based on individual data,
!Commitment from responsible authorities and key
stakeholders for quality assurance;
!Adequate legal and institutional support for quality
assurance throughout the screening process includ-
ing coordination, supervision and training, quality
control of equipment, computerised information
systems, and monitoring and evaluation;
! Supply of dedicated personnel and resources for
provision of multidisciplinary screening services
including testing, diagnosis, treatment, surveillance
and palliative care and for quality assurance.
!Expenditure for quality assurance of 10–20% as esti-
mated from costs of a fully established programme.
This expenditure also includes sustainable funding
for cancer and screening registries.
quality of the clinical pathway in the screening pro-
cess. This might also enable national or regional
screening registries to evolve into cancer-speciﬁc
quality registries or become part of the cancer
registry.Conﬂict of interest statement
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